A new study pinpoints how an immune checkpoint protein called LAG3 modulates T cell activity, providing important insights for development of LAG3-blocking therapies for cancer and autoimmune disorders.
A new study pinpoints how an immune checkpoint protein called LAG3 modulates T cell activity, providing important insights for development of LAG3-blocking therapies for cancer and autoimmune disorders.